Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Semin Nucl Med. 2016 Sep 3;46(6):502–506. doi: 10.1053/j.semnuclmed.2016.07.004

Fig. 3.

Fig. 3

Prediction of time to hormonal treatment failure with FDG PET-CT performed 4 months after the start of androgen deprivation therapy in 32 men with castrate-sensitive metastatic prostate cancer. The Kaplan-Meir survival curves show statistically significant difference in time to hormonal treatment failure when patients were dichotomized based on the median value of the most metabolically active lesion on scans (MAX = highest SUVmax of all active lesions).